author-photo

Yehuda E. Deutsch

University of Miami

22

Papers

141

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers.

2020 Journal of Oncology Practice
Show All
- Source
- Cite
- Save
Citations (2)
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Complete Response of Primary Refractory ALK+ Large B-cell Lymphoma treated with Single Agent Nivolumab

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

2019 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study

2018 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (29)
Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

2018 Blood
Show All
- Source
- Cite
- Save
Citations (5)